LivaNova PLC (NASDAQ:LIVN) Short Interest Down 18.6% in February

LivaNova PLC (NASDAQ:LIVN) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 1,580,000 shares, a decrease of 18.6% from the February 13th total of 1,940,000 shares. Approximately 2.9% of the company’s stock are sold short. Based on an average trading volume of 613,400 shares, the short-interest ratio is currently 2.6 days.

LivaNova Stock Performance

Shares of NASDAQ:LIVN traded up $0.43 during trading on Wednesday, hitting $40.84. 706,127 shares of the stock were exchanged, compared to its average volume of 601,254. LivaNova has a 1-year low of $36.85 and a 1-year high of $64.48. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of 97.24 and a beta of 1.10. The company’s fifty day simple moving average is $45.75 and its 200-day simple moving average is $48.94. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on LIVN shares. StockNews.com downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 26th. The Goldman Sachs Group cut their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Barclays cut their price target on LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a research note on Friday, March 7th. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus cut their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $61.17.

Institutional Trading of LivaNova

Several institutional investors have recently bought and sold shares of the stock. Jefferies Financial Group Inc. acquired a new stake in LivaNova in the 4th quarter valued at $4,812,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in LivaNova by 25.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 153,458 shares of the company’s stock valued at $7,107,000 after purchasing an additional 30,718 shares during the last quarter. Squarepoint Ops LLC raised its position in LivaNova by 74.3% in the 4th quarter. Squarepoint Ops LLC now owns 111,449 shares of the company’s stock valued at $5,161,000 after purchasing an additional 47,494 shares during the last quarter. Two Sigma Advisers LP raised its position in LivaNova by 148.5% in the 4th quarter. Two Sigma Advisers LP now owns 214,545 shares of the company’s stock valued at $9,936,000 after purchasing an additional 128,200 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in LivaNova by 27.2% in the 4th quarter. Two Sigma Investments LP now owns 439,582 shares of the company’s stock valued at $20,357,000 after purchasing an additional 93,985 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.